Phase 3 VISION Trial Shows Promising Results in Advanced Prostate Cancer
The use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death among patients with advanced prostate cancer.
In a recent interview with Pharmacy Times, medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer. These new findings will be presented at the American Society of Clinical Oncology 2021 annual meeting.
The trial was conducted in patients with metastatic, advanced prostate cancer whose disease was no longer responding to multiple other interventions. The trial had 2 primary endpoints: overall survival and radiographic progression-free survival. Morris said the use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death.
